Back to discover
Drug

Emollients

Regulatory activity · MHRA
Emerging researchLate-stage development

Also known as Emollient.

RxNorm3822
1
Research papers
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis

Clinical trial2023-12-19Results posted · ClinicalTrials.gov

Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019.

Research2020-03-29Dermatologic therapy

Drug Safety Update: Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients

Regulatory2018-12-18MHRA

An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

Clinical trial2017-07-11Results posted · ClinicalTrials.gov

Addition of a Topical Steroid to a Topical Retinoid: a Randomized, Split-face, Placebo-controlled, Double-blind, Single-center Clinical Study

Clinical trial2016-01-01Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Emollients
Aliases & brands
Emollient
RxNorm CUI
3822
Regulatory jurisdictions
mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
1
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2018-12-18Safety communicationSafety
Drug Safety Update: Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2020
2
Late-stage (III+)
2
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 3
Phase 21Phase 31Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis

CompletedPH IIISanofin=1652020

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes1
Health Personnel1
Journals, researchers & institutions
Top journals
  • Dermatologic therapy1
Leading researchers
  • Chen H1
  • Chen L1
  • Cheng B1
  • Diao P1
  • Dong L1
  • Gao X1
  • Gu H1
  • He L1
Leading institutions
free-text, unnormalised
  • Air Force General Hospital of PLA1
  • Chinese Medical University First Hospital1
  • First Affiliated Hospital of Fujian Medical University1
  • First Affiliated Hospital of Kunming Medical University1
  • Hainan Hospital of PLA General Hospital1
  • Hospital for Skin Diseases1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.